<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224117</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ211001</org_study_id>
    <nct_id>NCT03224117</nct_id>
  </id_info>
  <brief_title>Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat</brief_title>
  <acronym>SMF</acronym>
  <official_title>A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Finding Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DWJ211

      _ reduction of moderate or severe submental fat
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-grade response : PA-SMFRS</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>proportion of subject who simultaneously have at least a 2 grade improvement from baseline on the PA-SMFRS at 4weeks after the last treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2-grade response : SA-SMFRS</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>proportion of subject who simultaneously have at least a 2-grade improvement from baseline on the SA-SMFRS at 4weeks after the last treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-grade response : PA-SMFRS</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>proportion of subject who simultaneously have at least a 1-grade improvement from baseline on the PA-SMFRS at 4weeks after the last treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-grade response : SA-SMFRS</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>proportion of subject who simultaneously have at least a 1-grade improvement from baseline on the SA-SMFRS at 4weeks after the last treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI volume response rate</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>change rate of reduction in SMF volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement: SA-SMFIS</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>improvement in the Subject reported submental fat impact scale overall score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obtained 5 score : SSS</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>proportion of subjects who have more than 5 score on the SSS(somewhat satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thickness response rate : caliper</measure>
    <time_frame>4 week after last treatment</time_frame>
    <description>change rate of reduction in SMF volume</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Treatment for Submental Fat</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SQ injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWJ211_0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SQ injection with DWJ211 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWJ211_1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SQ injection with DWJ211 1.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWJ211_2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SQ injection with DWJ211 2.0%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ211</intervention_name>
    <description>inject the Drug into submental fat via subcutaneous</description>
    <arm_group_label>DWJ211_0.5%</arm_group_label>
    <arm_group_label>DWJ211_1%</arm_group_label>
    <arm_group_label>DWJ211_2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>inject the Drug into submental fat via subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. submental fat grade by the investigator as 2 or 3 using the PA-SMFRS and graded by the
             subject as 2 or 3 using the SA-SMFRS as determined on Visit 1.

          2. Dissatisfaction with the submental area expressed by the subject as a rating of 1~3
             using the SSS as determinded on Visit 1.

          3. less than 35kg/m2 in body mass index on Visit1.

          4. subject who will agree with the no treatment for the procedure that may affect to
             reduction or the submental fat.

          5. subject who will agree with maintaining their body weight.

        Exclusion Criteria:

          1. History of any intervention to treat SMF

          2. History of trauma associated with the chin or neck areas that in the judgement of the
             investigator may affect evaluation of safety or efficacy of treatment.

          3. Evidence of any cause of enlargement in the submental area.

          4. history or current symptoms of dysphagia.

          5. a result on coagulation tests that indicates the presence of any clinically
             significant bleeding disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom Joon Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yang-won Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong-hyun Won, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Asan medical center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-ang university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk university medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Asan medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

